Department of Toxicology and Cancer Biology, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
School of Public Health, Guangzhou Medical University, Guangzhou, Guangdong, P.R. China.
Theranostics. 2020 Jul 11;10(20):9050-9065. doi: 10.7150/thno.47897. eCollection 2020.
MCL-1 is up-regulated in cancer and a target for cancer treatment. How MCL-1 is up-regulated and whether MCL-1 up-regulation plays a role in tumorigenic process is not well-known. Arsenic and benzo(a)pyrene (BaP) are well-recognized lung carcinogens and we recently reported that arsenic and BaP co-exposure acts synergistically in inducing cancer stem cell (CSC)-like property and lung tumorigenesis. This study was performed to further investigate the underlying mechanism focusing on the role of MCL-1. The spheroid formation assay and nude mouse tumorigenesis assay were used to determine the CSC-like property and tumorigenicity of arsenic plus BaP co-exposure-transformed human bronchial epithelial BEAS-2B cells, respectively. Biochemical, pharmacological and genetic approaches were used to manipulate gene expressions, dissect signaling pathways and determine protein-protein interactions. Both loss-of-function and gain-of-function approaches were used to validate the role of MCL-1 in arsenic plus BaP co-exposure-enhanced CSC-like property and tumorigenicity. Arsenic plus BaP co-exposure-transformed cells express significantly higher protein levels of MCL-1 than the passage-matched control, arsenic or BaP exposure alone-transformed cells. Knocking down MCL-1 levels in arsenic plus BaP co-exposure-transformed cells significantly reduced their apoptosis resistance, CSC-like property and tumorigenicity in mice. Mechanistic studies revealed that arsenic plus BaP co-exposure up-regulates MCL-1 protein levels by synergistically activating the PI3K/Akt/mTOR pathway to increase the level of a deubiquitinase USP7, which in turn reduces the level of MCL-1 protein ubiquitination and prevents its subsequent proteasome degradation. The deubiquitinase USP7-mediated MCL-1 up-regulation enhances arsenic and BaP co-exposure-induced CSC-like property and tumorigenesis, providing the first evidence demonstrating that USP7 stabilizes MCL-1 protein during the tumorigenic process.
MCL-1 在癌症中上调,是癌症治疗的靶点。MCL-1 如何上调以及 MCL-1 上调是否在肿瘤发生过程中发挥作用尚不清楚。砷和苯并(a)芘(BaP)是公认的肺癌致癌物,我们最近报道砷和 BaP 共暴露协同作用诱导癌症干细胞(CSC)样特性和肺癌发生。本研究旨在进一步研究其潜在机制,重点研究 MCL-1 的作用。球体形成试验和裸鼠肿瘤发生试验分别用于确定砷加 BaP 共暴露转化的人支气管上皮 BEAS-2B 细胞的 CSC 样特性和致瘤性。采用生化、药理学和遗传学方法操纵基因表达,剖析信号通路并确定蛋白质-蛋白质相互作用。采用失活和过表达两种方法验证 MCL-1 在砷加 BaP 共暴露增强 CSC 样特性和致瘤性中的作用。砷加 BaP 共暴露转化的细胞表达的 MCL-1 蛋白水平明显高于传代匹配的对照细胞、单独砷或 BaP 暴露转化的细胞。在砷加 BaP 共暴露转化的细胞中敲低 MCL-1 水平,显著降低了其抗凋亡能力、CSC 样特性和在小鼠中的致瘤性。机制研究表明,砷加 BaP 共暴露通过协同激活 PI3K/Akt/mTOR 通路上调 MCL-1 蛋白水平,增加去泛素酶 USP7 的水平,从而降低 MCL-1 蛋白泛素化水平,阻止其随后的蛋白酶体降解。去泛素酶 USP7 介导的 MCL-1 上调增强了砷和 BaP 共暴露诱导的 CSC 样特性和肿瘤发生,首次证明了 USP7 在肿瘤发生过程中稳定 MCL-1 蛋白。